Advisory Board and Editors HIV

PeerJ Factsheet
A one-page facts and stats PDF, to help when considering journal options with your co-authors.
Download Factsheet
I told my colleagues that PeerJ is a journal where they need to publish if they want their paper to be published quickly and with the strict peer review expected from a good journal.
Sohath Vanegas,
PeerJ Author
View author feedback

Carole A Lunny

Carole Lunny is a postdoctoral fellow at the Cochrane Hypertension and Therapeutics Initiative, at the University of British Columbia, in Vancouver, Canada. Carole Lunny is a PhD graduate from Cochrane Australia, Monash University (June of 2018). Carole’s research interests involve methodological issues in conducting, interpreting, and reporting "overviews of systematic reviews".

Carole's PubMed publications can be found here: https://www.ncbi.nlm.nih.gov/pubmed/?term=lunny+c%5Bauthor%5D
She can be found on twitter @carole_lunny

She worked as a researcher and statistical analyst on systematic reviews and meta-analyses, randomised control trials, and observational studies. She has worked for international development organisations in the US, Canada, Singapore, Myanmar, Thailand and Mexico, including the Unites Nations Development Fund, UNICEF, and the International Union for Lung Diseases and Tuberculosis.

Carole's main research Interests: Research methodology, reporting guidelines for overviews of reviews, assessment of risk of bias of studies, publication bias, reviews of methods studies, evaluation of methods studies, overviews of systematic reviews methods, systematic reviews, Cochrane methods

ORCID ID: 0000-0002-7825-6765

Benoît Mâsse

After 11 years working at the University of Washington and the Fred Hutchinson Cancer Research Center, Dr. Mâsse moved back to Canada in August of 2010 and took a faculty appointment at the Université de Montreal as well as joining the Research Center at CHU-Ste-Justine. Overall, he has contributed to 85+ research grants since graduating in biostatistics from UNC-Chapel Hill in 1993. In addition to studies focused on HIV/AIDS, he has been involved in clinical trials and studies on children delinquent behavior; perinatal research; head and neck cancer chemoprevention; breast cancer; psychosocial and work environment studies on cardiovascular diseases, urinary infection, delirium in cancer palliative care, and pain management in early termination of pregnancy.

Dr. Mâsse has conducted multi-country large international trials in USA, Brazil, Canada, China, India, Russia, and in many countries of Africa. Since 2000, he has contributed to the research agenda of several large NIH networks by providing methodological support for the development of study protocols as well as providing the infrastructure to support the conduct of these studies. In 2006, Dr. Mâsse received a grant of over $US 25 millions from the NIH as the Principal Investigator responsible for establishing the Statistical Data Management Center for providing support to all international Phase I-II-III trials and observational studies conducted within the Microbicide Trials Network.

George N. Pavlakis

MD, Umuversity of Athens, Greece
PhD, Syracuse University, NY
Chief of the Human Retrovirus Section of the National Cancer Institute, USA

Interests: HIV pathogenesis, Molecular Biology, gene regulation, Biotechnology, protein engineering, cytokines, Immunotherapy, Vaccines, Nucleic acid vaccines, gene therapy

Steffanie A. Strathdee

Associate Dean of Global Health Sciences, Harold Simon Professor and Chief of the Division of Global Public Health in the Department of Medicine at the University of California San Diego School of Medicine. She is an infectious disease epidemiologist with expertise in HIV and STD prevention interventions. In 2009, she and her team were awarded the Leadership Award in International Collaboration from the National Institute on Drug Abuse (NIDA). She also holds a MERIT award from NIDA.

Ravi Tandon

I completed my Ph.D dissertation at the University of Zurich, Switzerland where the major focus of my PhD research project was the study of endogenous feline leukemia virus (enFeLV) in cats during exogenous feline leukemia virus (FeLV) infection. My interest in retroviruses led me into the HIV research after Ph.D. My postdoctoral research project at University of California, San Francisco was on HIV immunology. On completion of my Post Doc, I joined Dr Ndhlovu’s new laboratory at the University of Hawaii to pursue studies on HIV and Aging based on my expertise and experience to address a new area of HIV research in which have interest.

Currently my research work as an Assistant Professor at JNU, New Delhi, India is focused on aging in HIV-1-infected people. Approximately one in five individuals living with HIV infection in the United States is 50 years of age or older. This proportion continues to increase as HIV incidence remains stable and potent antiretroviral therapy has reduced the morbidity and mortality associated with HIV infection. However, premature aging and non-AIDS related morbidity including cancer seem to be a new big problem in HAART era. Chronic inflammation in treated HIV-1-infected subjects seems to play an important role in non-AIDS –related complications. The main goal of my research is to investigate the mechanism of HIV mediated accelerated aging/inflammation in HAART-suppressed HIV-1 infected people.

Carine Van Lint

After performing her PhD thesis at the National Institutes of Health (NIH, Bethesda, USA) from 1991 to 1994 and a postdoctoral fellowship in New York from 1994 to 1997, Carine Van Lint joined the Faculty of Sciences of the "Université Libre de Bruxelles" as the head of the Laboratory of Molecular Virology. As a biochemist, Carine Van Lint has developed for the last 25 years a specific interest for pathogenic retroviruses. Her laboratory is mainly studying the role played by epigenetic modifications (such as histone acetylation, histone methylation and DNA methylation) and by non-epigenetic regulatory elements in transcriptional latency and reactivation of HIV-1 (Human Immunodeficiency Virus type 1 - the ethiologic agent of the acquired immunodeficiency syndrome (AIDS)), BLV (Bovine Leukemia Virus - the etiologic agent of a chronic lymphoproliferative disease termed enzootic bovine leucosis) and HTLV-1 (Human T-cell leukemia virus 1 - the etiologic agent of an aggressive lymphoproliferative disease (Adult T-cell Leukemia/Lymphoma) and a neurological degenerative syndrome (tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM)).

Zhijin Wu

I develop statistical methodology and software for the analysis of -omics data. I am particularly interested in the regulation of transcription: the molecular mechanism as well as its association with disease.

Keisuke Yusa

Chief, Laboratory for Virus Safety, Division of Biological Chemistry & Biologicals, National Institute of Health Sciences